LU-01-1377, a SCLC having an EGFR L858R mutation, exhibited high sensitivity to TAVO412 treatment compared to amivantamab analogue, whereas the amivantamab analogue was not efficacious (Figure 2E). This evidence concerns the gene EGFR and small cell lung carcinoma.